Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures

摘要: Using data from ARISTOTLE, we describe the periprocedural management of anticoagulation and rates subsequent clinical outcomes among patients chronically anticoagulated with warfarin or apixaban. We recorded whether (and for how long) anticoagulant therapy was interrupted preprocedure, bridging used, proportion who experienced important during 30 days postprocedure. Of 10 674 procedures performed follow-up in 5924 patients, 9260 were included this analysis. Anticoagulant treatment not preprocedure 37.5% time. During postprocedure, stroke systemic embolism occurred after 16/4624 (0.35%) apixaban-treated 26/4530 (0.57%) warfarin-treated (odds ratio [OR] 0.601; 95% confidence interval [CI] 0.322-1.120). Major bleeding 74/4560 (1.62%) apixaban arm 86/4454 (1.93%) (OR 0.846; CI 0.614-1.166). The risk death similar (54/4624 [1.17%]) (49/4530 [1.08%]) 1.082; 0.733-1.598). Among 30-day postprocedure stroke, death, major low apixaban- regardless stopped beforehand. Our findings suggest that many on chronic can safely undergo procedures; some will require a interruption anticoagulation. ARISTOTLE registered at www.clinicaltrials.gov as #NCT00412984.